{"DataElement":{"publicId":"7391771","version":"2","preferredName":"Clinical Trial Phase Code","preferredDefinition":"A character or string that represents the stage in the lifecycle of a clinical trial.","longName":"PHASECD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"7391767","version":"1","preferredName":"Demographics Domain Clinical Trial Protocol Trial Phase","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics._A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. (ICH)_Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","longName":"6409089v1.0:7391765v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"6409089","version":"1","preferredName":"Demographics Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics.","longName":"C49572","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Demographics Domain","conceptCode":"C49572","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7405A2C5-47B3-4F68-E053-F662850A6AE3","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-22","modifiedBy":"ONEDATA","dateModified":"2018-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7391765","version":"1","preferredName":"Clinical Trial Protocol Trial Phase","preferredDefinition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. (ICH):Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","longName":"C142451:C48281","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Protocol","conceptCode":"C142451","definition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Trial Phase","conceptCode":"C48281","definition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB7D207-637D-1CD7-E053-4EBD850AABA9","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008529","version":"1","preferredName":"Research Protocols","preferredDefinition":"the identification of cancer research protocols.","longName":"RSCH_PROT","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECC2BE-2F27-348A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB7D207-638E-1CD7-E053-4EBD850AABA9","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-13","modifiedBy":"TAYLORT","dateModified":"2020-08-28","changeDescription":"CDASH NSV; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7391769","version":"1.1","preferredName":"Demographics Domain Clinical Trial Protocol Phase Code","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics._A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. (ICH)_Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"DMPHASECD","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"NONE","valueDescription":"None","ValueMeaning":{"publicId":"3030997","version":"1","preferredName":"None","longName":"3030997","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82DD865C-2FEA-9DF4-E040-BB89AD434EAA","latestVersionIndicator":"Yes","beginDate":"2010-03-28","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB54893-399F-4FE6-E053-731AD00A52F1","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-11-30","modifiedBy":"ONEDATA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"IIR","valueDescription":"Phase II Trial Randomized Clinical Trial","ValueMeaning":{"publicId":"7391770","version":"1","preferredName":"Phase II Trial Randomized Clinical Trial","longName":"7391770","preferredDefinition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention. \r\n: A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group. Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively. At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase II Trial","conceptCode":"C15601","definition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Randomized Clinical Trial","conceptCode":"C15417","definition":"Assignment of subjects by chance to groups that receive different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB51697-ACF9-5DD7-E053-4EBD850A1E01","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-13","modifiedBy":"TAYLORT","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB54893-39A0-4FE6-E053-731AD00A52F1","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-11-30","modifiedBy":"ONEDATA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"II","valueDescription":"Phase II Trial","ValueMeaning":{"publicId":"2578681","version":"1","preferredName":"Phase II Trial","longName":"2578681","preferredDefinition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention. \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase II Trial","conceptCode":"C15601","definition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0066-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"TAYLORT","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB54893-39A1-4FE6-E053-731AD00A52F1","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-11-30","modifiedBy":"ONEDATA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"I","valueDescription":"Phase I Trial","ValueMeaning":{"publicId":"2578679","version":"1","preferredName":"Phase I Trial","longName":"2578679","preferredDefinition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects. \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase I Trial","conceptCode":"C15600","definition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0064-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"TAYLORT","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB54893-39A2-4FE6-E053-731AD00A52F1","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-11-30","modifiedBy":"ONEDATA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"0","valueDescription":"Phase 0 Trial","ValueMeaning":{"publicId":"2698170","version":"1","preferredName":"Phase 0 Trial","longName":"2698170","preferredDefinition":"A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase 0 Trial","conceptCode":"C54721","definition":"A clinical trial that uses an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FEC515A-6612-1907-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2007-11-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB54893-39A3-4FE6-E053-731AD00A52F1","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-11-30","modifiedBy":"ONEDATA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"IR","valueDescription":"Phase I Trial Randomized Clinical Trial","ValueMeaning":{"publicId":"7556887","version":"1","preferredName":"Phase I Trial Randomized Clinical Trial","longName":"7556887","preferredDefinition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.: A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group. Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively. At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phase I Trial","conceptCode":"C15600","definition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Randomized Clinical Trial","conceptCode":"C15417","definition":"Assignment of subjects by chance to groups that receive different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9D1A021-20D3-5B83-E053-4EBD850AC8F5","latestVersionIndicator":"Yes","beginDate":"2021-01-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-01-26","modifiedBy":"ONEDATA","dateModified":"2021-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB54893-39A4-4FE6-E053-731AD00A52F1","beginDate":"2021-01-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-11-30","modifiedBy":"ONEDATA","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"Safety Phase 1","valueDescription":null,"ValueMeaning":{"publicId":"12118134","version":"1","preferredName":"Safety Phase I Trial","longName":"12118134v1.00","preferredDefinition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions._A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Safety","conceptCode":"C60828","definition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Phase I Trial","conceptCode":"C15600","definition":"A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEB592DE-AB1F-5AAB-E053-731AD00A07E1","latestVersionIndicator":"Yes","beginDate":"2022-11-30","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"RAGUNATHANU","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB592DE-AB20-5AAB-E053-731AD00A07E1","beginDate":"2022-11-30","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"RAGUNATHANU","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"Safety Phase II","valueDescription":null,"ValueMeaning":{"publicId":"12118135","version":"1","preferredName":"Safety Phase II Trial","longName":"12118135v1.00","preferredDefinition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions._A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Safety","conceptCode":"C60828","definition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Phase II Trial","conceptCode":"C15601","definition":"A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEB59AD2-5194-5B92-E053-731AD00A4D75","latestVersionIndicator":"Yes","beginDate":"2022-11-30","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"RAGUNATHANU","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB59AD2-5196-5B92-E053-731AD00A4D75","beginDate":"2022-11-30","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"RAGUNATHANU","dateModified":"2022-11-30","deletedIndicator":"No"},{"value":"Randomized Controlled Trial","valueDescription":null,"ValueMeaning":{"publicId":"12118136","version":"1","preferredName":"Randomized Controlled Clinical Trial","longName":"12118136v1.00","preferredDefinition":"A study in which the participants are assigned by chance to separate groups to evaluate treatments.  The study also includes a control group, which is undergoing the same rigors of the study with placebo treatment or standard treatment.  The trial can also be controlled by the addition of a test group to ensure there are no factors present to skew the results and by the inclusion of peer-review analysis by appropriate government officials. 2005","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Randomized Controlled Clinical Trial","conceptCode":"C46079","definition":"A study in which the participants are assigned by chance to separate groups to evaluate treatments.  The study also includes a control group, which is undergoing the same rigors of the study with placebo treatment or standard treatment.  The trial can also be controlled by the addition of a test group to ensure there are no factors present to skew the results and by the inclusion of peer-review analysis by appropriate government officials. 2005","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEB59AD2-5195-5B92-E053-731AD00A4D75","latestVersionIndicator":"Yes","beginDate":"2022-11-30","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"RAGUNATHANU","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEB59AD2-5197-5B92-E053-731AD00A4D75","beginDate":"2022-11-30","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"RAGUNATHANU","dateModified":"2022-11-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008529","version":"1","preferredName":"Research Protocols","preferredDefinition":"the identification of cancer research protocols.","longName":"RSCH_PROT","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECC2BE-2F27-348A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7391768","version":"1","preferredName":"Demographics Domain Clinical Trial Protocol Trial Phase Code","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics.:A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. (ICH):Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C49572:C142451:C48281:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Demographics Domain","conceptCode":"C49572","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Trial Protocol","conceptCode":"C142451","definition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Trial Phase","conceptCode":"C48281","definition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB51697-ACC6-5DD7-E053-4EBD850A1E01","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEB5478D-405A-4FD0-E053-731AD00AC9D9","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-11-30","modifiedBy":"SOKKERL","dateModified":"2023-06-02","changeDescription":"1/26/2020 TL added 1 PV.","administrativeNotes":"6/2/23 released PV added by Tina and versioned. LS","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Phase","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEDFAC77-8EBE-5CE8-E053-731AD00A9477","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-12-02","modifiedBy":"MMADDINENI","dateModified":"2023-01-31","changeDescription":"8.28.20 TL released/MM. CDASH NSV; TL.","administrativeNotes":"01/31/2023-VD upversioned as change in max length, CDE version changed-MM","unresolvedIssues":null,"deletedIndicator":"No"}}